WuXi STA is proceeding with a major multi-site, global expansion plan to enhance its manufacturing capabilities and capacities. Yu Lu, the Chief Business Officer of WuXi STA and Head of WuXi TIDES, detailed the expansion efforts across several key sites at the DCAT Member Company Announcement Forum held on March 18th, 2024, at DCAT Week.
The expansion efforts across several key sites, including the unveiling of its 169-acre active pharmaceutical ingredient (API) manufacturing facility in Taixing, China, alongside existing drug-product manufacturing facilities in Wuxi City, China, and Couvet, Switzerland, and forthcoming sites in Middletown, Delaware, and Tuas, Singapore.
